Cite

HARVARD Citation

    Rahmany, S. et al. (n.d.). PTU-073 In Patients with IBD Switching from Originator Infliximab (Remicade) to Biosimilar Infliximab (CT-P13) Is Safe and Effective. Gut. p. A89. [Online]. 
  
Back to record